FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE and CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Overview

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #10 most commonly reported adverse reaction for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 1,444 FDA adverse event reports linking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 2.1% of all 70,190 adverse event reports for this drug.

Patients taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.

Other Side Effects of FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:

• DYSPNOEA — 5,246 reports
• DRUG INEFFECTIVE — 3,162 reports
• PRODUCT DOSE OMISSION ISSUE — 2,933 reports
• WRONG TECHNIQUE IN DEVICE USAGE PROCESS — 2,925 reports
• PRODUCT COMPLAINT — 2,598 reports
• COUGH — 2,510 reports
• DEATH — 2,244 reports
• PNEUMONIA — 1,862 reports
• ASTHMA — 1,558 reports
• FATIGUE — 1,210 reports

Other Drugs Associated with CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:

Does FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE cause CHRONIC OBSTRUCTIVE PULMONARY DISEASE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 1,444 FDA reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC OBSTRUCTIVE PULMONARY DISEASE with FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 2.1% of all adverse event reports for FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.

What should I do if I experience CHRONIC OBSTRUCTIVE PULMONARY DISEASE while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

If you experience chronic obstructive pulmonary disease while taking FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages